Clinical Trials on Streptococcus Pyogenes Identification in South Africa

Total 68 results

GlaxoSmithKline

Completed

Feasibility Study for Identifying Anti Capsular Antibody Protection Against Invasive Group B Streptococcus (GBS) Disease in Newborns of 0-6 Days Age (Early Onset Disease [EOD]) as Well as Among Infants of 7-90 Days Age (Late Onset Disease [LOD])

Streptococcus Agalactiae

South Africa
Pfizer

Completed

Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants

Group B Streptococcus Infections

United States, South Africa, United Kingdom
Novartis
Novartis Vaccines

Withdrawn

Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 Days

Invasive Group B Streptococcus Disease

South Africa
University of Witwatersrand, South Africa
Novartis Vaccines

Completed

GBS Sero-correlate of Protection (V98_28OBTP)

Invasive Group B Streptococcus Disease

South Africa
Minervax ApS
European and Developing Countries Clinical Trials Partnership (EDCTP)

Completed

Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV

Group B Streptococcal Infection

South Africa, Uganda
GlaxoSmithKline

Completed

Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.

Infections, Streptococcal

South Africa
General and Maternity Hospital of Athens Elena...

Not yet recruiting

Efficacy of CompuFlo® Technology in Thoracic Epidural Space Identification

Thoracic Epidural Space Identification

Greece
Checkable Medical Inc
Curebase Inc.

Completed

Clinical Performance of the Checkable Medical At-Home Strep A Test

Respiratory Tract Infections | Pharyngitis | Streptococcus Pyogenes Infection

United States
Minervax ApS
Larix A/S

Completed

Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women

Group B Streptococcal Infection

Denmark, United Kingdom, South Africa
Novartis Vaccines

Completed

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age

Streptococcal Infections

South Africa
Novartis Vaccines

Completed

Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings

Bacterial Infections | Streptococcal Infections | Gram-Positive Bacterial Infections

South Africa, Malawi
University of Cape Town
Natal Bioproducts Institute

Completed

Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea

Sydenham Chorea | Post Streptococcal Movement Disorder

South Africa
Instituto de Atención Pediátrica
Pfizer; Ben-Gurion University of the Negev

Suspended

Costa Rica Epidemiological Study on S. Pneumoniae

Streptococcus Pneumoniae

Costa Rica
LEO Pharma

Completed

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

Secondarily Infected Traumatic Lesions | Impetigo

United States, South Africa
GlaxoSmithKline
Novartis Vaccines

Completed

Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women

Streptococcus Agalactiae | GBS Disease

United States
UNION therapeutics

Completed

Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Impetigo

South Africa
Pfizer

Completed

Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

HIV Infections | Pneumococcal Infections

South Africa, Romania
Ferrer Internacional S.A.

Completed

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Impetigo

Germany, South Africa
NovaBay Pharmaceuticals, Inc.

Completed

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

Impetigo

United States, South Africa
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) (PNEU-WAY)

Pneumococcal Infections

United States, France, Peru, South Africa, Thailand
GPN Vaccines

Recruiting

Extension Safety and Immunogenicity Study of GPNV-001

Pneumococcal Infections

Australia
GPN Vaccines

Recruiting

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

Pneumococcal Infections

Australia
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

Pneumococcal Infections

United States
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

Pneumococcal Infections

United States
Ellume Pty Ltd

Completed

Performance of Ellume·Lab Group A Strep Test Versus Culture for the Rapid Detection of Group A Streptococcus in Patients With Acute Pharyngitis.

Group A Streptococcal Infection

Australia
Royal North Shore Hospital

Unknown

Citriodiol® and Impetigo

Impetigo

Australia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) (PNEU-PATH)

Pneumococcal Infections

United States, Korea, Republic of, Spain, Taiwan
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

Pneumococcal Disease

United States, Belgium, Chile, France, South Africa, Thailand
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Pneumococcal Infections

United States, Australia, Canada, Chile, New Zealand, Poland, Russian Federation
Pfizer

Completed

Post Market Surveillance to Observe Safety of Prevenar13™ in Adults

Pneumococcal Disease

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED) (PNEU-WAY PED)

Pneumococcal Infections

South Africa, Thailand, Ukraine
Pfizer

Completed

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

Pneumococcal Infections

United States
Pfizer

Completed

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Pneumococcal Disease

United States
Pfizer

Terminated

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

Pneumococcal Infections

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Pneumococcal Infections

United States, Canada, Denmark, Finland, Israel, Spain
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

Pneumococcal Disease

United States, Sweden
Pfizer

Completed

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

Pneumococcal Disease

United States
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

Pneumococcal Disease

United States, Sweden
Pfizer

Completed

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

Pneumococcal Infections

United States
Affinivax, Inc.

Completed

A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

Healthy Volunteers | Pneumococcal Disease

United States
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

Pneumococcal Disease

United States
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

Pneumococcal Disease

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

Pneumococcal Infections

United States, Puerto Rico, Thailand, Turkey
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

Pneumococcal Disease

Spain, United States, Canada, Chile, Greece, Germany, Finland, Argentina, Czechia, Hungary, Puerto Rico
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

Pneumococcal Infections

United States, Australia, Belgium, Brazil, Canada, Colombia, France, Germany, Mexico, Sweden
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) (PNEU-PED-EU-1)

Pneumococcal Infections

Australia, Belgium, Czechia, Estonia, Germany, Greece, Poland, Russian Federation, Spain
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

Pneumococcal Infections

United States, Sweden
Pfizer

Completed

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Pneumococcal Disease

United States
Pfizer

Completed

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

Pneumococcal Infections

Sweden, United States, Germany
Murdoch Childrens Research Institute
Royal Children's Hospital

Completed

What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?

Primary Immunodeficiency | Invasive Pneumococcal Disease, Protection Against | Invasive Pneumococcal Disease, Recurrent Isolated, 1 | Invasive Pneumococcal Disease, Recurrent Isolated, 2

Australia, New Zealand

3

Subscribe